Targeted therapies and practical strategies for sleep disorders in Parkinson’s

Sleep problems affect between up to 80% of people living with Parkinson's, often becoming one of the most disruptive non motor symptoms. A clinical review published by Dr Cristian Falup Pecurariu and colleagues in the Journal of Parkinson's Disease brings together what current research reveals about why these sleep disturbances occur and, crucially, which targeted treatments offer genuine benefit. Sleep disruption in the condition is not a single issue with a single cure. It arises from damage to brain centres that regulate internal 24 hour clocks, lower natural melatonin production, nighttime movement difficulties, and the timing of certain daily medications. Consequently, treatment must be matched to the specific sleep problem taking place. Tackling insomnia and night waking Insomnia is the most frequent complaint, showing up as difficulty falling asleep or waking up repeatedly during the night. Non drug approaches are the essential first step. Cognitive Behavioural Therapy for Insomnia, tailored bright light exposure in the morning, and regular daytime exercise have established evidence for improving sleep onset and total sleep duration without side effects. When nighttime waking is caused by motor symptoms such as muscle stiffness, an inability to turn over in bed, or painful cramps, adjusting dopaminergic therapies makes a substantial difference: Continuous delivery via the rotigotine transdermal patch provides round the clock symptom coverage. It is formally rated as likely efficacious for managing sleep issues by the International Parkinson and Movement Disorder Society. Bedtime doses of controlled release carbidopa levodopa, sustained release pramipexole, or long acting ropinirole help alleviate nocturnal rigidity and ease turning over. In more advanced stages, advanced continuous delivery methods such as subcutaneous foslevodopa foscarbidopa infusions and intestinal gels significantly decrease nocturnal awakenings, early morning off periods, and nighttime urinary frequency. Where insomnia persists despite motor control, prescription options such as eszopiclone, low dose doxepin, or prolonged release melatonin are frequently used, while standard sedatives are approached cautiously due to daytime grogginess and fall risks. Managing rapid eye movement behaviour disorder Rapid eye movement sleep behaviour disorder involves acting out dreams through vivid vocalisations, punching, flailing, or thrashing. This happens because the natural brainstem mechanism that keeps muscles paralysed during dream sleep is impaired. The immediate priority is bedroom safety, including padding hard surfaces and lowering bed heights. Pharmacologically, high dose melatonin taken thirty to sixty minutes before bedtime serves as the preferred first line therapy because it calms dream enactment effectively with a favourable safety profile. Clonazepam is an alternative option, though doctors monitor its use carefully due to the potential for morning sedation or unsteadiness. Calming restless legs syndrome Restless legs syndrome creates an uncomfortable crawling or pulling sensation deep in the calves and thighs, producing an irresistible urge to move the legs that worsens in the evening and at rest. Clinical evaluation starts by checking serum ferritin and iron levels, as iron deficiency in the brain exacerbates restless legs. Correcting low iron can resolve or diminish symptoms. When pharmacological therapy is required, evening doses of dopamine agonists or gabapentinoids, such as gabapentin and pregabalin, help reduce sensations and allow uninterrupted sleep. Reducing excessive daytime sleepiness Excessive daytime sleepiness affects up to half of people with the condition. It can stem from poor nighttime sleep architecture, neurochemical changes in brain wakefulness networks, or the sedating side effects of daytime dopamine agonists. Management focuses on two main strategies: Reviewing daytime medications to ensure dopamine agonists are not triggering sudden sleep attacks, shifting doses where appropriate. Checking for obstructive sleep apnoea, which is frequently underdiagnosed and improves markedly with continuous positive airway pressure therapy. Where daytime drowsiness remains disabling despite good sleep hygiene, wakefulness promoting medications such as modafinil may be prescribed to help maintain alertness. The review emphasises that sleep problems should not be accepted as an inevitable complication. Identifying the exact nature of the disruption, whether it involves physical stiffness, dream enactment, restless sensations, or breathing difficulties, enables clinicians to select the specific therapeutic tool that restores restorative sleep.